prikaz prve stranice dokumenta The place of the botulinum toxin in the management of multiple sclerosis
  Download
PDF 143.92 KB
Scientific paper - Review paper
The place of the botulinum toxin in the management of multiple sclerosis
Clinical Neurology and Neurosurgery, 112 (2010), 7; 592-596. https://doi.org/10.1016/j.clineuro.2010.04.010
Habek, Mario; Karni, Arnon; Balash, Yakov; Gurevich, Tanya

Cite this document

Habek, M., Karni, A., Balash, Y. & Gurevich, T. (2010). The place of the botulinum toxin in the management of multiple sclerosis. Clinical Neurology and Neurosurgery, 112. (7), 592-596. doi: 10.1016/j.clineuro.2010.04.010

Habek, Mario, et al. "The place of the botulinum toxin in the management of multiple sclerosis." Clinical Neurology and Neurosurgery, vol. 112, no. 7, 2010, pp. 592-596. https://doi.org/10.1016/j.clineuro.2010.04.010

Habek, Mario, Arnon Karni, Yakov Balash and Tanya Gurevich. "The place of the botulinum toxin in the management of multiple sclerosis." Clinical Neurology and Neurosurgery 112, no. 7 (2010): 592-596. https://doi.org/10.1016/j.clineuro.2010.04.010

Habek, M., et al. (2010) 'The place of the botulinum toxin in the management of multiple sclerosis', Clinical Neurology and Neurosurgery, 112(7), pp. 592-596. doi: 10.1016/j.clineuro.2010.04.010

Habek M, Karni A, Balash Y, Gurevich T. The place of the botulinum toxin in the management of multiple sclerosis. Clinical Neurology and Neurosurgery [Internet]. 2010 September [cited 2025 February 13];112(7):592-596. doi: 10.1016/j.clineuro.2010.04.010

M. Habek, A. Karni, Y. Balash and T. Gurevich, "The place of the botulinum toxin in the management of multiple sclerosis", Clinical Neurology and Neurosurgery, vol. 112, no. 7, pp. 592-596, September 2010. [Online]. Available at: https://urn.nsk.hr/urn:nbn:hr:105:327287. [Accessed: 13 February 2025]

Please login to the repository to save this object to your list.
Metadata
Title (english)The place of the botulinum toxin in the management of multiple sclerosis
AuthorMario Habek
AuthorArnon Karni
AuthorYakov Balash
AuthorTanya Gurevich
Author's institutionUniversity of Zagreb
School of Medicine
Scientific / art field,
discipline and subdiscipline		BIOMEDICINE AND HEALTHCARE
Clinical Medical Sciences
Abstract (english)
Multiple sclerosis (MS) is the most common disabling chronic disease of the central nervous system among young adults. These patients suffer from variety of symptoms that have a profound affect on their working ability, activities of daily living and general quality of life. Treatment of these symptoms is important in order to relief them and improve daily function and quality of life. Many of these symptoms are often resistant to treatment. Botulinum toxin A (BTX) is mainly used for spasticity and bladder dysfunction in MS. It is an effective treatment option for spasticity of the thigh adductor, pes equinus, striatal toe or adductor of the shoulder joint. BTX injections are effective in reducing incontinence episodes and urinary urgency, daytime frequency and nocturia, as well as sustained improvements in quality of life of MS patients with detrusor overreactivity. In addition, BTX is potentially effective in treating pain, trigeminal neuralgia, tremor, neuro-ophthalmologic complications, facial myokymia, gastroparesis, sialorrhea, and hyperhidrosis, however no studies have confirmed its efficacy in MS patients.
Keywords (english)
Languageenglish
Publication typeScientific paper - Review paper
Publication statusPublished
Peer reviewPeer review
Publication versionAccepted version
Journal titleClinical Neurology and Neurosurgery
Numberingvol. 112, no. 7, pp. 592-596
p-ISSN0303-8467
DOIhttps://doi.org/10.1016/j.clineuro.2010.04.010
URN:NBNurn:nbn:hr:105:327287
Publication2010-09
Document URLhttps://doi.org/10.1016/j.clineuro.2010.04.010
Type of resourceText
Access conditionsOpen access
Terms of useLicence In copyright icon
Created on2024-03-28 11:56:48